| scholarly article | Q13442814 |
| P50 | author | Manuel Battegay | Q62559552 |
| Philip E Tarr | Q91425500 | ||
| Swiss HIV Cohort Study | Q33121558 | ||
| P2093 | author name string | A Calmy | |
| A Nguyen | |||
| B Hirschel | |||
| E Bernasconi | |||
| J-M Evison | |||
| M Opravil | |||
| P Schmid | |||
| T Perneger | |||
| V Schiffer | |||
| P2860 | cites work | An objective case definition of lipodystrophy in HIV-infected adults: a case-control study | Q44350196 |
| Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy | Q44406903 | ||
| Risk factors for lipodystrophy in the CISAI cohort | Q44677707 | ||
| Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial | Q44686476 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine | Q45739557 | ||
| Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. | Q45754658 | ||
| Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 | ||
| A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy | Q57181107 | ||
| Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy | Q31831126 | ||
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 | ||
| Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study | Q34091370 | ||
| Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial | Q34136715 | ||
| TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy | Q34153600 | ||
| Acquired and inherited lipodystrophies | Q34306820 | ||
| What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection | Q35748475 | ||
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 | ||
| Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients | Q36223917 | ||
| Appearance-related side effects of HIV-1 treatment | Q36373511 | ||
| Toxic metabolic syndrome associated with HAART. | Q36544924 | ||
| The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics | Q38483733 | ||
| Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group | Q39309934 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance | Q43950417 | ||
| Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study | Q44156639 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 142-150 | |
| P577 | publication date | 2008-01-22 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. | |
| P478 | volume | 9 |
| Q33797575 | Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy |
| Q37111867 | Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia |
| Q40100018 | Cardiovascular risk and dyslipidemia among persons living with HIV: a review |
| Q59340042 | Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race |
| Q46959264 | Cohort profile: the Swiss HIV Cohort study |
| Q41756147 | Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults |
| Q36077885 | Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings |
| Q38963668 | Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? |
| Q36903976 | Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction |
| Q58798012 | From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection |
| Q90436693 | Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa |
| Q34655845 | HIV-associated lipodystrophy: impact of antiretroviral therapy. |
| Q28088839 | HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings |
| Q58797959 | High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy |
| Q37423288 | Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution |
| Q88029274 | Incidence and Risk Factors for Overweight and Obesity after Initiation of Antiretroviral Therapy in Dar es Salaam, Tanzania |
| Q34066641 | Increased aldosterone among HIV-infected women with visceral fat accumulation |
| Q34502149 | Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention |
| Q35913712 | Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls |
| Q36068146 | Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART). |
| Q40613036 | Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study |
| Q39123448 | Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study |
| Q37419698 | Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot study |
| Q38061798 | Nutrition and the HIV-associated lipodystrophy syndrome |
| Q34802246 | Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study |
| Q35898696 | Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). |
| Q28748901 | Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection |
| Q34637395 | Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. |
| Q38421020 | The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection |
| Q33995992 | The role of aldosteronism in causing obesity-related cardiovascular risk |
| Q36505451 | Thymidine analogues suppress autophagy and adipogenesis in cultured adipocytes |
| Q43179931 | Utility of atazanavir in special populations |
Search more.